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Abstract
Background: Uncomplicated urinary tract infections (UTI) are a frequent reason for consultation of women in
primary health care. To avoid therapy failure and development of resistances, the choice of an antibiotic should be
based on the knowledge of recent local resistance data but these data are scarce for the Austrian primary health
care sector. Within the context of the ECO·SENS II study it was the aim to obtain appropriate and relevant local
resistance data and describe the changes in the resistance pattern in comparison to the ECO·SENS study.
Methods: 23 GPs from different parts of Austria participated in the study between July 2007 and November 2008.
According to the defined inclusion- and exclusion criteria female patients with symptoms of an uncomplicated UTI
were included and a midstream urine sample was collected. In case of significant bacteriuria susceptibility testing of
E. coli against 14 antibiotics was performed. Descriptive statistical methods were used.
Results: In 313 patients included in the study, a total of 147 E. coli isolates (47%) were detected and tested. The
resistance rates were in %: Mecillinam (0.0), nitrofurantoin (0.7), fosfomycin trometamol (0.7), gentamycin (1.4),
cefotaxime (2.7), ceftazidime (2.7), Cephadroxil (4.1) and ciprofloxacin (4.1). Higher resistance rates were found in
amoxicillin/clavulanic acid (8.9), nalidixic acid (9.6), trimethoprim/sulphamethoxazole (14.4), trimethoprim (15.8),
sulphamethoxazole (21.2) and ampicillin (28.8). Additionally, the comparison of these results with the results of the
ECO·SENS study demonstrated an increase in resistance rates of ampicillin, amoxicillin/clavulanic acid, nalidixic acid
and ciprofloxacin.
Conclusions: The resistance data for E. coli in uncomplicated UTIs in women gained by this study are the most
recent data for this disease in Austria at the moment. The increased resistance rates of amoxicillin/clavulanic acid,
ciprofloxacin and nalidixic acid should be respected when choosing an appropriate antibiotic for uncomplicated
UTIs. The use of ampicillin, sulphamethoxazole, trimethoprim and trimethoprim/sulphametoxazole in uncomplicated
UTIs in women should be questioned at all. The findings of this study should result in a regular surveillance system
of resistances emerging in the ambulatory sector designed after the model of the EARS-Net.
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Background
Urinary tract infections (UTI) are a frequent reason for
consultation of women in primary health care [1-4].
According to epidemiological surveys an annual inci-
dence of 11.3 million cases in the USA and 175 million
cases worldwide can be estimated [5,6]. Approximately
80% of the cases with a significant positive urine culture
for pathogens an infection with Escherichia coli (E. coli)
can be expected; other causative bacteria are Staphylo-
coccus saprophytic us, Klebsiella pneumonia, Proteus
mirabilis and group B streptococci [7,8].
The natural course of these UTIs shows a low rate of
spontaneous cure even after a follow up of 6 weeks [9].
Since UTIs are a frequent reason for prescribing antibio-
tics (AB) the decision which AB should be prescribed
has to be considered prudently. Normally, when antibio-
tics for treating an acute UTI are prescribed in primary
health care the nature of the causative bacterium can
only be presumed because current resistance data from
the primary health care sector are scarce [10-12]. How-
ever, to avoid the increasing threat of antibiotic resis-
tances the local resistance patterns, especially for UTIs
where resistances to commonly used antibiotics like
ampicillin and trimethoprim are increasing, have to be
respected [13-17]. Therefore, it is necessary to gain sus-
ceptibility data especially from the primary health care
sector and not only from hospitals or specialized centre’s
because these resistances differ from that seen in the
ambulatory sector [18].
Some studies on this topic have been performed. One
has been the ECO·SENS project [17]. It was an inter-
national survey to investigate the prevalence and suscepti-
bility of uropathogens causing acute uncomplicated
community-acquired UTIs in primary care in the years
1999 and 2000. Collectively, 4,734 women with symptoms
of acute UTI from 252 community care centre’s in 16
European countries including Austria and, in addition,
Canada were enrolled. A total of 3,278 women (69.2%)
had culture proven lower UTIs with E. coli responsible for
77% of all culture proven pathogens. Six years later a simi-
lar project, ECO·SENS II was conducted to provide and
follow up data on epidemiology and susceptibility of uro-
pathogens causing UTIs in primary care in 5 European
countries: United Kingdom, Sweden, Austria, Portugal
and Greece. In the context of the ECO·SENS II study it is
the aim of the present analysis to provide data about the
antimicrobial susceptibility of E. coli and K. pneumonia
causing uncomplicated UTIs in women in primary health
care in Austria and to compare the corresponding data of
the ECO·SENS project (1999-2000) with the ECO·SENS II
project (2007-2008) data. In addition, these results were
contrasted with the resistance data for E. coli in the
Austrian resistance report 2008 (AURES) for the ambu-
latory sector [15].
Methods
Patients and investigational centre’s
This study was designed as a cross-sectional study. Dur-
ing the study period from July 2007 to November 2008,
all female patients aged 18- 65 years that consulted one
of their GPs in 23 GP offices (investigational centre’s)
with symptoms of uncomplicated UTI were included
consecutively, if they met the inclusion criteria and
agreed to sign the informed consent form. The investiga-
tional centre’s that had to subscribe an informed consent
form too, were located in three geographical regions in
Austria each separated from the other by at least
150 km. The geographical regions included larger cities
as well as smaller cities and rural areas.
From the ECO·SENS study it was known that approxi-
mately 70% of the subjects included had an infection
with uropathogens of which approximately 77% were E.
coli. Therefore, it was the aim of the investigational cen-
tre’s to include 400 subjects to ensure that 200 isolates
of E. coli were collected.
Inclusion and exclusion criteria
Inclusion criteria: Female patients aged 18- 65 years with
uncomplicated UTI.
After adequate information and signing the informed
consent forms, the patients were asked to assess the pres-
ence and severity of 4 typical symptoms of an uncompli-
cated UTI: Frequency, urgency, dysuria and suprapubic
pain. Presence and severity was assessed as follows: 0 = ab-
sent, 1 =mild, 2 =moderate and 3 = severe. The sum of the
4 symptoms gave the total symptom score (range 0-12).
Only patients with a symptom score of ≥ 2 were included in
the study.
Exclusion criteria: Symptoms lasting more than 7 days,
signs of infection of the upper urinary tract, known struc-
tural or functional abnormalities of the urinary tract,
indwelling urinary catheter or chronic incontinence, sub-
jects who had received any kind of antibiotics within the
previous 2 weeks for UTI or any other cause or who had
received medically prescribed treatment for more than 3
UTIs in the past 12 months, subjects suffering from im-
munosuppression, CNS-disorders or venereal diseases, sub-
jects with diabetic retinopathy, nephropathy or neuropathy,
subjects who currently participated in any clinical study or
previously enrolled in this survey, subjects who had
received treatment with an investigational product within
the last 3 months and subjects who were known to be
pregnant.
Materials
The urine cultures were carried out for the purposes of
this study only. Patients were required to provide a
freshly voided midstream urine sample. Immediately
after sampling, an Uricult dip slide was prepared and
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forwarded by courier to the central laboratory for micro-
biological testing (Laboratory for Clinical Microbiology,
Central Hospital, Växjö, Sweden). No dipstick testing for
leucocytes was performed in advance due to the impos-
sibility to exclude an UTI by a negative result [17,19].
After the arrival at the central microbiological laboratory
the dip slide was incubated for 18-24 hours at 35°C fol-
lowed by assessing the bacterial density of the original
urine sample leading to one of four possible results:
A positive result means a Gram-negative culture and ≥
103 cfu/ml, a negative result means no growth or < 103 cfu/
ml, mixed means the presence of more than two species,
other means the growth of Gram-positive bacteria.
Significant bacteriuria was defined as ≥ 103 cfu/ml as
there is evidence that a significant number of women
with symptoms of UTI do not have bacteriuria exceed-
ing this value [20]. Further, this value corresponds to the
lower limit of the former ECO·SENS survey [17].
Qualitative assessment was done by sub-culturing for
identification and testing for antibiotic susceptibility of E.
coli and K. pneumonia. The isolates were tested against
the following antimicrobial agents: Mecillinam, ampicillin,
amoxicillin + clavulanic acid, sulphametoxazole trimethoprim,
trimethoprim/sulfamethoxazole, ciprofloxacin, nalidixic acid,
nitrofurantoin, gentamicin, fosfomycin/trometamol, Cepha-
droxil, cefotaxime and ceftazidime. The susceptibility of E. coli
and K. pneumonia is expressed by inhibition zone sizes and
grouped as susceptible or resistant in accordance with the
results of the disk diffusion method and the corresponding
breakpoint values published by the Swedish Reference Group
for Antibiotics [21]. The distribution of mecillinamin MIC-
values for both E. coli and K. pneumonia isolates was deter-
mined by EtestW.
In addition to the antibiotic resistance data, demo-
graphic data (age) of the patients related were documen-
ted by the GPs. The age was stratified into two clusters:
The first one with patients aged 18-50 years, the second
one with patients aged 51-65 years.
Data analysis
The prevalence of the bacteria were described first in re-
lation to all included urine samples and then in relation
to all cultures with a significant growth. Statistically sig-
nificant differences in the frequency of E.coli in the dif-
ferent age subgroups were performed by using the
Pearson’s Chi-Square test (alpha 5%; CI 95%). The resist-
ance rates for E.coli and K.pneumoniae were described
for each of the 14 antibiotics by conduction descriptive
statistical methods.
The most frequent combinations of multi-resistances
to antimicrobial agents were listed along their propor-
tions and exact confidence intervals.
Additionally, the proportion of resistant E. coli isolates
and exact confidence intervals were contrasted with the
findings from the original ECO·SENS project. Changes
between the resistance rates of the two studies were
described. Moreover, these results were contrasted with
the resistance data for E. coli in the Austrian resistance
report 2008 (AURES) for the ambulatory sector to show
possible differences.
Ethical considerations




Within the study period of 71.4 weeks a total of 1,776
subjects were enrolled in the ECO·SENS II study in all
five countries of which 1,697 cases could be analyzed.
Figure 1 shows the flow chart for the sampling and
analyzing process for patients, urine samples and bacter-
ial specimens for Austria. In Austria 23 primary care in-
vestigational centre’s recruited 327 patients of which 14
had to be refused due to the exclusion criteria. The 313
remaining patients had a mean age of 40.2 (SD 14.8)
years and a mean total symptom score of 5.5 (SD 2.7).
Figure 1 Flow chart for the recruiting, sampling and testing
process for patients, urine samples and bacterial specimens.
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All 313 urine samples of these patients were included in
the further analyses. Overall, there has been a significant
bacterial growth in 64% (n = 200) of the 313 urine sam-
ples. Table 1 shows the distribution of all culture test
results, first, in relation to all 313 samples and, in
addition, in relation to the 200 samples with bacterial
growth.
Concerning the two age cluster no statistically signifi-
cant difference in the prevalence of E. coli in relation to
all 313 samples (48.8% in age group 18-50 years vs.
44.0% in age group 51-65 years; p > 0.05) or in relation
to the 200 samples with a positive culture growth (75.2%
vs. 71.3%; p > 0.05) could be found.
Due to the very low number of K. pneumonia isolates
found (n = 3) they were excluded from any further
calculations.
Resistance data
Table 2 shows the antimicrobial resistance rates of the E.
coli isolates against 14 antibiotics. The antimicrobial resist-
ance as described in the table was very low for mecillinam
(MEC), nitrofurantoin (NIT), fosfomycin trometamol (FOS)
and gentamycin (GEN), low for cefotaxime (CTX), ceftazi-
dime (CAZ), Cephadroxil (CDR) and ciprofloxacin (CIP),
higher for amoxicillin/clavulanic acid (AMC), nalidixic
acid (NAL), trimethoprim/sulphamezoxazole (TSU)and tri-
methoprim (TRI) and highest for sulphamethoxazole (SUL)
and ampicillin (AMP).
In total, 91 (62.3%) of the 146 isolates were susceptible
to all tested antibiotics, 16 (10.9%) isolates were resistant
to one antibiotic, 12 (8.2%) were resistant to two, 8 (5.5%)
isolates to three and 19 (13.1%) isolates to four and more
antibiotics. Figure 2 describes the distribution of the 55
(37.7%) single and multi-resistant E. coli isolates. For Aus-
tria 20 different multi-resistant phenotypes were found in
E. coli. The most common resistance types were AMP-
SUL (4.11%; CI 1.52- 8.73), AMP-TRI-SUL-TSU (3.42%;
CI 1.12- 7.81), TRI-SUL-TSU (3.42%; CI 1.12- 7.81),
AMP-AMC (2.74%; CI 0.75- 6.87), AMP-AMC-TRI-SUL-
TSU (2.05%; CI 0.43- 5.89) and AMP-TRI-SUL-TSU-
NAL-CIP (1.37%; CI 0.17- 4.86). All other resistance phe-
notypes had an equal frequency of 0.68% (CI 0.02- 3.76).
The isolate with the highest number of resistances to
different antibiotics was resistant to AMP-AMC-TRI-
SUL-TSU-NAL-CIP-CDR-CTX-CAZ.
The susceptibility testing of the 146 E. coli isolates with
mecillinam demonstrated that 50.7% had MIC values of
0.125 Mg/L and 17.8% had MIC values of 0.25 Mg/L.
Two ESBL producing isolates of E. coli were detected
both belonging to the CTX-M-1 group. The MIC values
ranged from 64 to 256 mg/L for cefotaxime and from 16
to 256 mg/L for ceftazidime. Both strains were suscep-
tible to mecillinam with MIC values between 0.38 and
1.0 mg/l. No ESBL producing strains of K. pneumonia
were found.
Comparison of the results from ECO·SENS, ECO·SENS II
and the results from the Austrian resistance report 2008
for E. coli for the ambulatory sector
Table 3 describes the differences in the resistance find-
ings of E. coli against 12 antibiotics of the ECO·SENS
Table 1 Distribution of all culture test results in relation to all 313 samples and in relation to the 200 samples with
bacterial growth
Culture results No. of all cultures (%) No. of positive cultures (%)
(n = 313) (n = 200)
E. coli 147 (47%) 147 (73.5%)
K. pneumonia 3 (1%) 3 (1.5%)
Other uropathogens* 50 (16%) 50 (25.0%)
Non-pathogens or negative or mixed§ cultures 113 (37%) -
*Proteus mirabilis, Klebsiella spp., other Enterobacteriaceae, Staphylococcus saprophyticus, enterococci and Pseudomonas spp.
§Mixed means more than two species.
Table 2 Antimicrobial resistances to 14 antimicrobial
agents of the 146 E. coli strains
Antimicrobial agent % (95% CI) (N = 146*)
Mecillinam 0.00 (0.00 - 2.49) (n = 0)
Ampicillin 28.77 (21.58 – 36.83) (n = 42)
Amoxicillin/clavulanic acid 8.90 (4.83 – 14.74) (n = 13)
Trimethoprim 15.75 (10.26 - 22.69) (n = 23)
Sulphamethoxazole 21.23 (14.91 – 28.76) (n = 31)
Trimethoprim/Sulphamethoxazole 14.38 (9.13 – 21.14) (n = 21)
Nalidixic acid 9.59 (5.34 – 15.57) (n = 14)
Nitrofurantoin 0.68 (0.02 – 3.76) (n = 1)
Ciprofloxacin 4.11 (1.52 – 8.73) (n = 6)
Gentamicin 1.37 (0.17 – 4.86) (n = 2)
Fosfomycin trometamol 0.68 (0.2 – 3.76) (n = 1)
Cefadroxil 4.11 (1.52 – 8.73) (n = 6)
Cefotaxime 2.74 (0.75 – 6.87) (n = 4)
Ceftazidime 2.74 (0.75 – 6.87) (n = 4)
Since there are resistances against more than one antibiotic the sum of the
absolute numbers exceeds 146.
* The antimicrobial resistance result of one isolate is missing.
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Figure 2 Distribution of the 55 single and multi-resistant E. coli isolates. The bars represent the absolute numbers of isolates in which
resistance against “1” to “10” different antibiotics were observed at the same time. The percentages indicate the distribution within this sample.
Table 3 Comparison of resistance rates among E. coli in Austria between ECO·SENS and ECO·SENS II and contrasting
these data with the E. coli resistance data in the Austrian resistance report 2008 for the ambulatory sector
Antibiotic Resistance rates Resistance rates Trend between
ECO•SENS and
ECO•SENS II
E. coli resistance data in
the Austria resistance
report 2008 for the
ambulatory sector, n (%)
ECO•SENS ECO•SENS II
(N = 126), n (%) (N = 146), n (%)
Mecillinam 2 (1.6) 0 (0.0) ↘ 4,361 (12.2)
Ampicillin 22 (17.5) 42 (28.8) ↗ 8,992 (39.8)
Amoxicillin/clavulanic acid 3 (2.4) 13 (8.9) ↗ 8,985 (5.8)
Trimethoprim 12 (9.5) 23 (15.8) ↗ -
Sulphamethoxazole 32 (25.4) 31 (21.3) ↘ -
Trimethoprim/Sulphamethoxazole 12 (9.5) 21 (14.4) ↗ 8,992 (24.6)
Nalidixic acid 3 (2.4) 14 (9.6) ↗ -
Nitrofurantoin 1 (0.8) 1 (0.7) ↘ 8,789 (2.2)
Ciprofloxacin 0 (0.0) 6 (4.1) ↗ 8,992 (15.7)
Gentamicin 1 (0.8) 2 (1.4) ↗ 8,990 (4.7)
Fosfomycin trometamol 0 (0) 1 (0.7) ↗ 5,489 (1.5)
Cefadroxil 1 (0.8) 6 (4.1) 9,088 (8.5)
Cefotaxime Not tested 4 (2.7) -
Ceftazidime Not tested 4 (2.7) -
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and ECO·SENS II studies and the results from the Aus-
trian resistance report 2008 for E. coli for the ambula-
tory sector.
An increase in microbial resistance against ampicillin,
amoxicillin/clavulanic acid, nalidixic acid and ciprofloxa-
cin could be observed between the study period of the
ECO·SENS study in 1999/2000 and the ECO·SENS II
study in 2007/2008.
By contrasting the results of the ECO·SENS II study
with the results from the Austrian resistance report 2008
for the ambulatory sector, the resistance results in the
Austrian resistance report 2008 were much higher. Ampi-
cillin (39.8%), trimethoprim/sulphamethoxazole (24.6%)
and ciprofloxacin (15.7%) were the AB with the highest re-
sistance rates for E. coli but also mecillinan (12.2%),
Cephadroxil (8.5%) and nitrofurantoin (2.2%) showed
much higher resistance rates compared to the ECO·SENS
II study.
Discussion
The resistance data for E. coli in uncomplicated UTIs in
18-65 year old women gained by this study are the most
recent data for this disease in Austria at this moment
[12]. Moreover, Austria participated in both surveys in
the ECO·SENS 1999/2000 as well as in the ECO·SENS II
2007/2008. For this reason changes in the antibiotic
resistances could be described between these two peri-
ods and interpreted with caution. The chance to conduct
such a comparison was due to the number given by the
centre’s (19/23), the number of patients recruited (298/
327), the mean age (41.0/40.2) and the symptom score
(5.4/5.5) were similar and the inclusion/exclusion criteria
as well as the study procedures, the laboratory and the
susceptibility testing according to the Swedish Reference
Group for Antibiotics and its Subcommittee on Method-
ology (SRGA) [21] for the two studies were identical.
Nevertheless, it has to be considered that this compari-
son is between two cross-sectional studies and, there-
fore, it has limitations which were discussed below.
The study showed that 47% of women complaining of
symptoms of an uncomplicated UTI had significant bac-
teriuria caused by E. coli which is 73.4% of all grown
bacteria; a percentage very similar to the results found
in the ECO·SENS study nine years before and the
ARESC study from 2006 [16,17].
Concerning the resistance patterns of E. coli the study
showed that mean resistance rates of ampicillin (28.8%),
sulphametoxazole (14.4%), trimethoprim (15.8%) and tri-
methoprim/sulphametoxazole (14.4%) remained high or
even increased (ampicillin) between the years 1999/2000
and 2007/2008. Lower mean resistance levels were found
for nalidixic acid (9.6%), amoxicillin/clavulanic acid
(8.9%), ciprofloxacin (4.1%) and Cephadroxil (4.1%),
with a change (except Cephadroxil) in resistance rates
between the two ECO·SENS studies. Resistance rates
of mecillinam (0%), nitrofurantoin (0.7%), fosfomycin
(0.7%), gentamycin (1.4%), cefotaxime (2.7%) and ceftazi-
dime (2.7%) remained very low. Based on the literature
we could confirm the persisting very low resistance rate
for mecillinam [8].
Fortunately, the resistance of E. coli to nitrofurantoin
and fosfomycin were both less than 1% since these two
antibiotics are recommended in the S3-guideline for the
treatment of uncomplicated UTI as first-line drugs [22]
but how is the prescribing behavior of GPs and what do
local guidelines recommend? For instance the Austrian
ABSGROUP recommend pivmecillinam, amoxicillin/cla-
vulanic acid and sultamicillin as first-line drugs [23]. For
amoxillin/clavulanic acid the resistance rate in the ECO·-
SENSE II study for Austria was 8.9% which is not yet
alarming but a negative trend. Therefore, our study can
promote further surveillance of antibiotic resistance, es-
pecially, in the primary health care sector not only to
check the currentness of guidelines but also the make
the GPs think about their own prescribing behavior, not
only in Austria.
Only 2 (1.4%) ESBL producing isolates of E. coli and
no ESBL producing strain of K. pneumonia were found
which is comparable to a study from France with low
level of ESBL (1.2%) in uncomplicated UTIs in outpati-
ents [24].
The quite high and compared to the results of the
ECO·SENS study increased resistance rates of amoxicil-
lin/clavulanic acid, ciprofloxacin and nalidixic acid
should be respected when choosing an appropriate anti-
biotic for uncomplicated UTIs. The use of ampicillin,
sulphamethoxazole, trimethoprim and trimethoprim/sul-
phametoxazole in uncomplicated UTIs in women should
be questioned as suggested by the even higher resistance
results of the ARESC-study (48.3% for ampicillin and
29.0% for trimethoprim/sulphametoxazole) [16].
The increase in fluorochinolon resistance is not yet
alarming but deserves further careful observation taking
into consideration the increasing use of this antibiotic in
uncomplicated UTIs [25,26].
The comparison of the resistance rates of this study with
the corresponding rates of the Austrian Resistance Report
2008 (AURES) shows much higher resistance rates for
aminopenicillin, fluorochinolon and trimethoprim/sulpha-
metoxazole as well as a higher rates to mecillinam in the
AURES 2008 [15]. The reason for the higher resistance
rates described in the AURES 2008 may result from the
different data collection methodology. In the AURES the
resistance data for all E. coli specimens sent to one of the
reference laboratories are described. In a routine primary
health care setting, samples from the primary care sector
are sent predominantly to a laboratory if a complicated
UTI occurred. Therefore, these data do not fit as reference
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data for local or national guidelines. However, in a lot of
countries data collected like these are the only available
which should be questioned. To obtain comprehensive re-
sistance data for uncomplicated UTIs that have to find
their way into the guidelines, clearly structured studies
have to be performed on a regular base.
The missing resistance testing of uropathogens like
other Enterobacteriaceae and Staphylococcus saprophytic
us as well as the low numbers of K. pneumonia isolates
and the exclusion of mixed cultures can be considered
as limitation of this study. Further limitations were the
patients and GPs inclusion process which was consecu-
tive and voluntary. It could be speculated that the GPs
that were already sensible concerning the topic antibiotic
resistance and prudent antibiotic prescription partici-
pated in this study only. Moreover, the comparison of
the results of two cross-sectional studies has to be ques-
tioned due to the lack of knowledge concerning further
demographic data of the participating patients and the
non-exact matching of the participating GP offices.
Conclusions
The resistance data found are an important contribution
to the therapeutic safety and quality in General Practice
in Austria.
Since there is a growing concern about an increase in
antibiotic resistance also in the ambulatory sector due to
frequent and sometimes uncritical prescriptions of anti-
biotics the results of this study could help to estimate
the scope of the problem by increasing the knowledge
about antibiotic resistance pattern before a possible ther-
apy is prescribed. The knowledge of changes in anti-
biotic resistance over time is the next essential step for
choosing the appropriate antibiotic [27]. The findings of
this study should result in a regular surveillance system
for bacteria and resistances emerging in the ambulatory
sector designed after the model of the EARS-Net (formerly
EARSS, European Antimicrobial Resistance Surveillance
System) [28] for women and for men. It is not enough to
sample and test all specimens coming to a laboratory from
the ambulatory sector by chance to obtain comprehensive
resistance data for the primary health care sector for spe-
cial diseases. Structured studies have to be performed on a
regular base. In addition to a surveillance system, more
UTI preventive interventions should be promoted [29].
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